author-photo

Shiangtung W. Jung

17

Papers

653

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy.

2021 Neurology and Therapy
Show All
- Source
- Cite
- Save
Citations (5)
Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with end-stage renal disease

2021 Kidney International Reports
Show All
- Source
- Cite
- Save
Citations (0)
Early Data on Long-Term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis: A 2-Year Update From the Open-Label Extension of the NEURO-TTR Trial.

2020 European Journal of Neurology
Show All
- Source
- Cite
- Save
Citations (18)
Mnis+7 And Lower Limb Function In Inotersen Treatment Of Hattr

2020 Muscle & Nerve
Show All
- Source
- Cite
- Save
Citations (1)
Neuropathy Symptom and Change: Inotersen Treatment of Hereditary Transthyretin Amyloidosis

2020 Muscle & Nerve
Show All
- Source
- Cite
- Save
Citations (2)
Responsiveness of Neuropathy Symptom and Change (NSC) Score Components in Inotersen Treatment of Hereditary Transthyretin Amyloidosis Polyneuropathy (P3.9-060)

2019 Neurology
Show All
- Source
- Cite
- Save
Citations (0)
SAFETY OF INOTERSEN TREATMENT IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

2019 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (2)
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial

2018 Amyloid
Show All
- Source
- Cite
- Save
Citations (12)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

2018
Show All
- Source
- Cite
- Save
Citations (0)
Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial

2018
Show All
- Source
- Cite
- Save
Citations (0)